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SYNOPSIS
Pyruvate kinase (PYK) plays a central role in the metabolism of many organisms and cell types,
but the elucidation of the details of its function in a systems biology context has been hampered by
the lack of specific high-affinity small molecule inhibitors. High-throughput screening has been
used to identify a family of saccharin derivatives which inhibit Leishmania mexicana PYK
(LmPYK) activity in a time- (and dose-) dependent manner; a characteristic of irreversible
inhibition. The crystal structure of 4-[(1,1-dioxo-1,2-benzothiazol-3-yl)sulfanyl]benzoic acid
(DBS) complexed with LmPYK shows that the saccharin moiety reacts with an active-site lysine
residue (Lys335), forming a covalent bond and sterically hindering the binding of ADP/ATP.
Mutation of the lysine residue to an arginine residue eliminated the effect of the inhibitor
molecule, providing confirmation of the proposed inhibitor mechanism. This lysine residue is
conserved in the active sites of the four human PYK isoenzymes, which were also found to be
irreversibly inhibited by DBS. X-ray structures of PYK isoforms show structural differences at the
DBS binding pocket, and this covalent inhibitor of PYK provides a chemical scaffold for the
design of new families of potentially isoform-specific irreversible inhibitors.
Keywords
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INTRODUCTION
Pyruvate kinase (PYK) catalyses the last step in glycolysis to produce ATP and pyruvate,
and in most organisms studied, PYKs have similar homotetrameric architectures with each
1To whom correspondence should be addressed: Centre for Translational and Chemical Biology, School of Biological Sciences, The
University of Edinburgh, Michael Swann Building, The King’s Buildings, Mayfield Road, Edinburgh EH9 3JR, UK. Tel.: 44 (0) 131
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The atomic co-ordinates of the LmPYK-DBS structure have been deposited in the PDB under code 3SRK.
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monomer composed of four domains (Figure 1a). Four human tissue-specific PYK
isoenzymes have been described: HsRPYK (erythrocyte), HsLPYK (liver), HsM1PYK
(muscle) and HsM2PYK (embryonic or tumour). The M1 isoform is constitutively active
while the other three are allosterically regulated by the effector molecule fructose 1,6-
bisphosphate (F16BP) [1]. Trypanosomatid PYKs are distinguished by their use of the
chemically distinct molecule fructose 2,6-bisphosphate (F26BP) as the effector, and recently
the detailed allosteric mechanism for PYK of the pathogenic protist Leishmania mexicana
(LmPYK) has been elucidated [2].
PYK has been implicated as playing a central role in a number of proliferative and infectious
diseases, and the discovery of isoenzyme-specific inhibitors or activators of PYK could be
of potential interest in the elucidation of the etiology of cancer [3] and of metabolic diseases
such as diabetes and obesity [4], as well as infectious diseases caused by bacteria [5],
trypanosomatid parasites [6] and the malaria parasites Plasmodium spp. [7]. For example,
PYK deficiency in erythrocytes results in nonspherocytic haemolytic anemia and over 130
mutations in HsRPYK have been identified which contribute to the disease [8, 9]. There is
also a strong link between the up-regulation of the human M2PYK isoenzyme and
oncogenesis [3], and this isoenzyme is found in all tumours studied to date [3]. The effector-
regulated HsM2PYK can facilitate a build-up of phosphometabolites which are required for
the cancer cell to proliferate. A number of potent activators of HsM2PYK have been
identified with AC50 values around 30 nM [10], however the only examples of HsM2PYK
inhibitors bind relatively weakly with IC50 values of 10 to 20 µM [11].
RNAi knockdown of PYK and other enzymes in the glycolytic pathway in trypanosomatids
has facilitated a systems biology approach to elucidate the roles played by these enzymes
[12]. A complementary approach to regulate PYK activity by small molecule compounds
has been hindered by the lack of appropriate chemical tools. One of the few compounds
currently available is the polysulfonated drug suramin, one of the earliest synthetic drugs
used to treat human African trypanosomiasis. It is a promiscuous binder with a complex
pharmacology and poorly understood mode of action. However, it has been shown to inhibit
seven of the ten enzymes in the glycolytic pathway of Trypanosoma brucei [13, 14]. A
crystal structure of a complex of LmPYK with suramin shows that it acts as an ATP/ADP
mimic and binds competitively with the ADP substrate [15]. Suramin also inhibits all four
human isoforms of PYK with Ki values between 1 and 20 µM [15]. In addition, affinity
labelling of rabbit-muscle PYK has been achieved by covalent modification of active-site
residues using nucleotide analogues [16] [17]. The only other known general PYK inhibitor
is the substrate analogue oxalate, which exhibits poor specificity and binds with relatively
weak affinity (Ki = 220 µM) [18]. Selective inhibitors of PYK are needed as biochemical
tools for studying the glycolytic pathway and as potential leads for drug development. Here
we report the discovery of a novel covalent PYK inhibitor, 4-[(1,1-dioxo-1,2-
benzothiazol-3-yl)sulfanyl]benzoic acid (DBS, Figure 1c).
EXPERIMENTAL
Expression and purification of wild-type and Lys335Arg mutant forms of LmPYK
Chemically competent Escherichia coli Rosetta 2* (DE3)pLysS (Merck – Cat. No. 71403)
cells were transformed with either the wild-type or mutated plasmid (see Supplementary
data). Both wild-type and Lys335Arg mutant forms of LmPYK were expressed and purified
as described previously [15].
Synthesis and characterization of covalent inhibitors
A series of saccharin derivatives identified as inhibitors of LmPYK by quantitative high-
throughput screening (qHTS) was further elaborated by de novo chemical synthesis,
Morgan et al. Page 2
Biochem J. Author manuscript; available in PMC 2012 November 15.
$watermark-text
$watermark-text
$watermark-text
purification and characterization. The procedures for the synthesis and purification of
compounds NCG00186526, NCGC00059857, NCGC00188411 and NCGC00188636
(Figure 1c) and their characterization are described in detail in the Supplementary data. One
of these analogues, DBS (NCGC00188636), displayed improved stability and solubility
profiles relative to the original screening hit (NCGC00186526) and was therefore used for
the experiments described in this paper.
PYK inhibitor assay
The following reagents were added to a 50 mL Falcon tube (equivalent to 11×1 mL assays):
8.58 mL of assay mix (1x assay buffer (50 mM triethanolamine (TEA), pH 7.2, 100 mM
potassium chloride, 3 mM magnesium chloride, 10% glycerol), 0.2 mM NADH (128023-
Roche), 3.2 U/mL lactate dehydrogenase (Sigma-61309)), 1.6 U/mL LmPYK, 0.4 mM
phosphoenolpyruvate (PEP) (Sigma- 79430) and 2.20 mL of 250 µM inhibitor solution
(made up with 1x assay buffer from a 170 mM stock in 100% DMSO, final conc. 50 µM –
added last to the reaction mix). The control reaction mix was made identically except 1x
buffer was used in place of the inhibitor solution. Both the control and inhibitor reaction
mixtures were incubated throughout the experiment in a 25 °C water bath (prior to the
addition of inhibitor which was also incubated at 25 °C). To 990 µL of the reaction mix, 10
µL of 20 mM ADP (final concentration = 0.2 mM ADP (Sigma-A4386); made up with 1x
assay buffer) was added to start the reaction. The mixture was gently agitated and the
decrease in absorbance at 340 nm was measured for 2 min (using Lambda Bio). The process
was repeated every 20 min over 200 min for both the control and inhibitor. The initial rate
was then calculated using UV kinlab. The rate for each inhibitor assay was expressed as a
percentage of the control assay.
Preparation of inhibitor-modified LmPYK
The DBS inhibitor (Stock = 172 mM in 100% dimethylsulfoxide (DMSO)) was added to
200 µL of LmPYK (10 mg/mL: 184 µM in 20 mM TEA buffer (pH 7.2) and 10% glycerol)
to a final concentration of 9 mM (maintaining a similar molar ratio of inhibitor to protein as
used in the kinetic assay). The sample was then incubated overnight at 4 °C. Dithiothreitol
(DTT) was added to a final concentration of 1 mM, and the LmPYK-DBS inhibitor mix was
incubated at room temperature for 15 min. The DTT and leaving group were removed by
repeated dilutions (using 20 mM TEA buffer (pH 7.2) and 10% glycerol) and by
concentrating the sample in a Vivaspin column (molecular mass cut off = 100 kDa). The
sample was concentrated to 12 mg/mL.
Crystallization and data collection
Samples of inhibitor-modified LmPYK (prepared as described) were diluted to 10 mg/mL
using a buffer containing 20 mM TEA (pH 7.2) and 1,3,6,8-pyrenetetrasulfonic acid (PTS,
final concentration 1 mM). Single crystals of inhibitor-modified LmPYK complexed with
PTS were obtained at 4 °C by vapour diffusion using the hanging drop technique. The drops
were formed by mixing 1.5 µL of protein solution with 1.5 µL of a well solution, composed
of 12 – 16% polyethyleneglycol (PEG) 8,000, 20 mM TEA buffer (pH 7.2), 50 mM
magnesium chloride, 100 mM potassium chloride and 10% glycerol. The drops were
equilibrated against a reservoir filled with 0.5 mL of well solution. Crystals grew to
maximum dimensions (1.0×0.2×0.1 mm) after 24 – 48 h. Prior to data collection, crystals
were equilibrated for 14 h over a well solution composed of 14 – 18% PEG 8,000, 20 mM
TEA buffer (pH 7.2), 50 mM magnesium chloride, 100 mM potassium chloride and 25%
glycerol, which eliminated the appearance of ice rings. Intensity data were collected (φscans
were 2° over 180°) at the Diamond synchrotron radiation facility in Oxfordshire, United
Kingdom on beamline IO3 from a single crystal cryocooled in liquid nitrogen. A single
crystal gave data to a resolution of 2.65 Å at 100 K.
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Structure determination and analysis of model geometry
The LmPYK-DBS structure was solved and refined using the method described previously
[2], yielding R/Rfree values of 21.9/27.35. A further round of TLS restrained refinement
(four optimal TLS groups were determined using TLSMD procedure [19]) yielded final R/
Rfree values of 22.3/26.6. The geometry of the model was assessed using MolProbity [20].
Although electron density was well defined for Thr296 (a key active-site residue), it exhibits
geometry outwith the Ramachandran plot here and in many PYK structures. This is
primarily due to a restricted geometry, which facilitates interactions with active-site ligands.
RESULTS AND DISCUSSION
High-throughput screening identified a series of saccharin-based inhibitors
There were 292,740 compounds in the NIH Molecular Libraries-Small Molecule Repository
tested in the primary screen for the wild-type LmPYK (PubChem AID 1721). The screen
was performed at seven compound concentrations using quantitative high-throughput
screening (qHTS) [21, 22] and identified 1,087 high-quality concentration-response curves,
corresponding to a hit rate of 0.4% of the library. One of the top actives from this series was
the saccharin derivative NCGC00186526, with an IC50 of 10 µM. The oxo linkage in this
compound was labile, and the molecule was found to hydrolyse to saccharin and the
corresponding phenol (Figure 1c). Stable sulphur (NCGC00188411) and nitrogen
(NCGC00059857) analogues were prepared (Figure 1c) and tested in the LmPYK activity
assay. Only NCGC00188411 showed inhibitory activity (IC50 = 5 µM). At this point it was
hypothesized that covalent modification of either cysteine or lysine in the enzyme, as well as
the leaving group ability of the resultant phenol, thiophenol and aniline explained the trend
in activity [23]. The sulphur analogue (4-[(1,1-dioxo-1,2-benzothiazol-3-yl)sulfanyl]benzoic
acid (DBS, NCGC00188636, Figure 1c and 1d) was used in subsequent experiments.
Covalent modification of LmPYK by DBS is confirmed by X-ray crystal structure analysis
LmPYK crystals grown in the presence of 2 mM oxalate and 2.8 mM DBS (LmPYK-OX/
DBS) were anisotropic, and diffracted poorly to approximately 4 Å. Despite the relatively
low resolution, difference (Fo-Fc) electron density was observed near Lys335 in all active
sites (Figure 1b) suggesting that Lys335 was covalently modified by the saccharin moiety
(Figure 1d). Improved quality crystals diffracting to 2.65 Å were obtained using a
purification protocol of DBS-modified LmPYK in which DMSO was removed by dilution
and PTS was added to the crystallization solution (see Table 1 for data collection and
refinement statistics). Electron density corresponding to the covalent addition of the
saccharin moiety to Lys335 is clearly visible in all active sites (Figure 1b). The modified
Lys335 residue is located at the adenine-binding site and blocks ADP/ATP binding (Figure
2a). Electron density was carefully examined around all other lysines in the structure but no
evidence for their covalent modification was observed.
Inhibition of LmPYK by DBS is time dependent
An inhibition assay was used to examine the covalent reaction further, whereby LmPYK
activity was monitored over time in the presence of 50 µM DBS (Figure 3d). Maximal
inhibition of ~80% was achieved after ~250 min (Figure 1e, curve A), although LmPYK
inhibition never reached 100% inhibition even after 10 h (after prolonged incubation periods
at 25 °C both the wild-type and Lys335Arg of LmPYK mutant began to aggregate). The
small amount of remaining activity could possibly be due to weak binding of ADP to the
DBS-modified active site. The X-ray structure of the modified enzyme suggests that the
saccharin group covalently bound to Lys335 with its flexible side chain could adopt
conformations that would still allow ADP access to the active site (Figure 2a), albeit with
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reduced affinity. In terms of potential antiparasitic activity it is relevant to note that
incomplete depletion (about 75%) of the intracellular concentration of PYK by RNAi is
sufficient to cause cell death in the pathogenic bloodstream form of T. brucei [24].
The Lys335Arg mutation confirms the covalent inhibitory mechanism
To test whether inhibition stems from the covalent modification of Lys335 and not
modification of other lysine residues in PYK, we expressed and purified the Lys335Arg
mutant of LmPYK. The wildtype and Lys335Arg mutant of LmPYK enzymes exhibited
similar activity and kinetic parameters (Supplementary Table S1). However, on addition of
DBS and under identical assay conditions to that of wild-type LmPYK, the Lys335Arg
mutant exhibited essentially no change in activity over time (Figure 1e, curve D).
Evidence of selectivity of DBS for Lys335 is suggested by the inability of DBS to inhibit
rabbit lactate dehydrogenase (a coupling enzyme) through covalent modification of a similar
active-site lysine, Lys56. This residue is similar in both location (found also on the rim of
the active site cleft) and interaction (interacting with the ribose hydroxyl of the nucleoside
group of NAD) to Lys335 of LmPYK (Supplementary Figure S3). A lysine residue
(Lys531) also exists in the active site of firefly luciferase (PDB code 2DIT). Both these
coupling enzymes provide good controls to suggest that DBS displays selectivity for binding
Lys335. The X-ray structural results discussed in the following section provide a rationale
for this specificity.
Mechanism of covalent modification by DBS is suggested by the structure of LmPYK-
suramin
A series of phenyl sulfonated dye-like molecules including the trypanocidal drug suramin
has been shown to bind in a near-identical position within the active site of LmPYK [15].
The LmPYK-DBS monomer was superimposed onto the LmPYK-suramin structure, with
excellent alignment of the protein backbones (RMS fit = 0.5 Å). Modelling a fit of the
sulfonamide group of the unreacted DBS molecule onto the sulfone group in the suramin
complex, perfectly positions Lys335 for nucleophilic attack on C3 of the saccharin ring to
release the sulphide moiety (Figures 1d, 2). The requirement for DBS to dock in such a
specific pose could explain its specificity for Lys335 over other lysine residues in the
structure. The X-ray structure however suggests that once the covalent bond has formed, the
modified lysine adopts a different pose. Comparisons of the relevant X-ray structures show
the sulphone groups of suramin and of the saccharin moiety of DBS covalently attached to
Lys335 are 4.4 Å apart (Figure 2b and Supplementary Figure S3).
DBS is a covalent inhibitor of both human and trypanosomatid PYKs
Lysine 335 is relatively well conserved among different PYK species and it is of interest that
naturally occurring mutations in HsRPYK (equivalent residue Lys410) to either glutamic
acid [9] or aspartic acid [25] result in non-spherocytic haemolytic anaemia. DBS was found
to inhibit both HsRPYK (the human PYK isoenzyme present in erythrocytes) and
HsM2PYK (the human PYK isoenzyme present in embryonic and tumour cells) with IC50
values of 8 µM and 16.3 µM, respectively (see Supplementary Figure S4). These values
compare with an IC50 value of DBS for LmPYK of 2.9 µM. Modelled poses of the pre-
cleavage DBS binding pocket highlight sequence differences between the trypanosomatid
and human enzymes (Figure 2d) and it is likely that such differences in the saccharin
binding pocket provide an opportunity for the design of more potent species-specific
inhibitors against either trypanosomatid or human PYK isoforms.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used
DBS 4-[(1,1-dioxo-1,2-benzothiazol-3-yl)sulfanyl]benzoic acid, compound
number NCGC00188636
DEAE diethylaminoethyl
DMF N,N-dimethylformamide
DMSO dimethylsulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
ESI-MS electrospray ionization mass spectrometry
Et3N triethylamine
F16BP fructose 1,6-bisphosphate
F26BP fructose 2,6-bisphosphate
HPLC high-performance liquid chromatography
HsPYK human pyruvate kinase
HsRPYK human erythrocyte PYK
HsLPYK human liver PYK
HsM1PYK human muscle PYK
HsM2PYK human embryonic or tumour PYK
LmPYK Leishmania mexicana PYK
MLSMR Molecular Libraries Small Molecule Repository
PEG polyethyleneglycol
PEP phosphoenolpyruvate
PTS 1,3,6,8-pyrenetetrasulfonic acid
PYK pyruvate kinase
qHTS quantitative high-throughput screening
TEA triethanolamine
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TFA trifluoroacetic acid
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Figure 1. Proposed reaction mechanism of DBS
(a) The four-domain structure of LmPYK-OX/DBS is indicated by different colours: green,
short N-terminal domain; purple, domain A, blue; domain B; yellow, domain C. The large
(a-a) and small (c-c) subunit interfaces are indicated by dotted lines. The black box
designates the position of the active site of one subunit, and is shown in close up in panel b.
(b) The difference (Fo-Fc map shown in green at a resolution of 3.5 Å, contoured to 2.5 σ)
electron density observed in all four active sites is associated with Lys335 in a novel
orientation (blue). (c) Two-dimensional structures of (NCGC00188411), (NCGC00186526)
(NCGC00059857) qHTS compared with the structure of the synthesised analogue
NCGC00188636 (DBS) that displayed enhanced stability and solubility. (d) The proposed
reaction mechanism for the covalent modification of Lys335. (e) Time-dependent inhibition
Morgan et al. Page 9
Biochem J. Author manuscript; available in PMC 2012 November 15.
$watermark-text
$watermark-text
$watermark-text
of LmPYK by pre-incubation with 50 µM DBS under variable conditions. (A) LmPYK pre-
incubated with 0.4 mM PEP and 50 µM DBS. (B) LmPYK pre-incubated with 0.4 mM PEP
(no inhibitor). (C) LmPYK pre-incubated with 0.4 mM PEP, 4 µM F26BP and 50 µM DBS.
(D) LmPYKΔK335R pre-incubated with 0.4 mM PEP and 50 µM DBS.
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Figure 2. DBS reacts with Lys335 at the active site of LmPYK
All ligands and interacting amino-acid residues are shown as sticks, and waters as red
spheres. (a) The superpositions of the ATP and the modified Lys335 indicate that the ATP/
ADP binding may be sterically hindered. (b) The proposed position of Lys335 prior to
covalent modification is shown by purple sticks. Initially the sulphur dioxide group of the
DBS molecule (pink sticks) binds to the active site, occupying a similar position to the
sulphono group of suramin (LmPYK-suramin structure [15], see Supplementary Figure S4).
The network of interactions (dashed red line = interactions <3 Å, dashed yellow lines =
interactions 3–4 Å, dashed green lines = coordination of the inorganic cations) hold DBS in
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place, providing an ideal reactive geometry for the reaction with Lys335 to occur. (c) Final
refined position of covalently modified Lys335 as observed in the crystal structure. (d)
Overlay of the X-ray structures of LmPYK (this paper) and the X-ray structure of
HsM2PYK showing differences in the amino acid side chains in three regions (R1, R2 R3)
around the modified Lys335 (yellow) that could enable the design of isoenzyme-specific
families of inhibitors.
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Table 1
Data collection and refinement statistics
Values in parentheses are for the highest-resolution shell.
Data collection
Space group I222
Cell dimensions
a, b, c (Å) 122.4 , 130.2, 166.5
Solvent content (%) 60.00
Wavelength (Å) 0.98
Resolution (Å) 60.85-2.65 (2.79-2.65)
Rsym 0.09 (0.64)
I / σ(I) 8.3 (1.7)
Completeness (%) 98.0 (98.8)
Redundancy 2.8 (2.8)
Refinement
Resolution (Å) 60.85-2.65
No. reflections 35936
Rwork / Rfree 22.3/26.6
Average protein B-factor (Å2) 31.4
No. Residues 894
R.m.s. deviations
     Bond lengths (Å) 0.01
     Bond angles (°) 0.90
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